Pharmacogenetics of azathioprine in inflammatory bowel disease: A role for glutathione-S-transferase?

Gabriele Stocco, Marco Pelin, Raffaella Franca, Sara De Iudicibus, Eva Cuzzoni, Diego Favretto, Stefano Martelossi, Alessandro Ventura, Giuliana Decorti

Research output: Contribution to journalArticle

Abstract

Azathioprine is a purine antimetabolite drug commonly used to treat inflammatory bowel disease (IBD). In vivo it is active after reaction with reduced glutathione (GSH) and conversion to mercaptopurine. Although this reaction may occur spontaneously, the presence of isoforms M and A of the enzyme glutathione-S-transferase (GST) may increase its speed. Indeed, in pediatric patients with IBD, deletion of GST-M1, which determines reduced enzymatic activity, was recently associated with reduced sensitivity to azathioprine and reduced production of azathioprine active metabolites. In addition to increase the activation of azathioprine to mercaptopurine, GSTs may contribute to azathioprine effects even by modulating GSH consumption, oxidative stress and apoptosis. Therefore, genetic polymorphisms in genes for GSTs may be useful to predict response to azathioprine even if more in vitro and clinical validation studies are needed.

Original languageEnglish
Pages (from-to)3534-3541
Number of pages8
JournalWorld Journal of Gastroenterology
Volume20
Issue number13
DOIs
Publication statusPublished - Apr 7 2014

Fingerprint

Pharmacogenetics
Azathioprine
Glutathione Transferase
Inflammatory Bowel Diseases
6-Mercaptopurine
Antimetabolites
Validation Studies
Genetic Polymorphisms
Glutathione
Protein Isoforms
Oxidative Stress
Pediatrics
Apoptosis
Enzymes
Pharmaceutical Preparations
Genes

Keywords

  • Azathioprine
  • Glutathione-S-transferase
  • Inflammatory bowel disease
  • Pediatric patients
  • Pharmacogenetics

ASJC Scopus subject areas

  • Gastroenterology
  • Medicine(all)

Cite this

Pharmacogenetics of azathioprine in inflammatory bowel disease : A role for glutathione-S-transferase? / Stocco, Gabriele; Pelin, Marco; Franca, Raffaella; De Iudicibus, Sara; Cuzzoni, Eva; Favretto, Diego; Martelossi, Stefano; Ventura, Alessandro; Decorti, Giuliana.

In: World Journal of Gastroenterology, Vol. 20, No. 13, 07.04.2014, p. 3534-3541.

Research output: Contribution to journalArticle

Stocco, Gabriele ; Pelin, Marco ; Franca, Raffaella ; De Iudicibus, Sara ; Cuzzoni, Eva ; Favretto, Diego ; Martelossi, Stefano ; Ventura, Alessandro ; Decorti, Giuliana. / Pharmacogenetics of azathioprine in inflammatory bowel disease : A role for glutathione-S-transferase?. In: World Journal of Gastroenterology. 2014 ; Vol. 20, No. 13. pp. 3534-3541.
@article{6dda4722a1074a3f97d7003bbd1b4246,
title = "Pharmacogenetics of azathioprine in inflammatory bowel disease: A role for glutathione-S-transferase?",
abstract = "Azathioprine is a purine antimetabolite drug commonly used to treat inflammatory bowel disease (IBD). In vivo it is active after reaction with reduced glutathione (GSH) and conversion to mercaptopurine. Although this reaction may occur spontaneously, the presence of isoforms M and A of the enzyme glutathione-S-transferase (GST) may increase its speed. Indeed, in pediatric patients with IBD, deletion of GST-M1, which determines reduced enzymatic activity, was recently associated with reduced sensitivity to azathioprine and reduced production of azathioprine active metabolites. In addition to increase the activation of azathioprine to mercaptopurine, GSTs may contribute to azathioprine effects even by modulating GSH consumption, oxidative stress and apoptosis. Therefore, genetic polymorphisms in genes for GSTs may be useful to predict response to azathioprine even if more in vitro and clinical validation studies are needed.",
keywords = "Azathioprine, Glutathione-S-transferase, Inflammatory bowel disease, Pediatric patients, Pharmacogenetics",
author = "Gabriele Stocco and Marco Pelin and Raffaella Franca and {De Iudicibus}, Sara and Eva Cuzzoni and Diego Favretto and Stefano Martelossi and Alessandro Ventura and Giuliana Decorti",
year = "2014",
month = "4",
day = "7",
doi = "10.3748/wjg.v20.i13.3534",
language = "English",
volume = "20",
pages = "3534--3541",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "13",

}

TY - JOUR

T1 - Pharmacogenetics of azathioprine in inflammatory bowel disease

T2 - A role for glutathione-S-transferase?

AU - Stocco, Gabriele

AU - Pelin, Marco

AU - Franca, Raffaella

AU - De Iudicibus, Sara

AU - Cuzzoni, Eva

AU - Favretto, Diego

AU - Martelossi, Stefano

AU - Ventura, Alessandro

AU - Decorti, Giuliana

PY - 2014/4/7

Y1 - 2014/4/7

N2 - Azathioprine is a purine antimetabolite drug commonly used to treat inflammatory bowel disease (IBD). In vivo it is active after reaction with reduced glutathione (GSH) and conversion to mercaptopurine. Although this reaction may occur spontaneously, the presence of isoforms M and A of the enzyme glutathione-S-transferase (GST) may increase its speed. Indeed, in pediatric patients with IBD, deletion of GST-M1, which determines reduced enzymatic activity, was recently associated with reduced sensitivity to azathioprine and reduced production of azathioprine active metabolites. In addition to increase the activation of azathioprine to mercaptopurine, GSTs may contribute to azathioprine effects even by modulating GSH consumption, oxidative stress and apoptosis. Therefore, genetic polymorphisms in genes for GSTs may be useful to predict response to azathioprine even if more in vitro and clinical validation studies are needed.

AB - Azathioprine is a purine antimetabolite drug commonly used to treat inflammatory bowel disease (IBD). In vivo it is active after reaction with reduced glutathione (GSH) and conversion to mercaptopurine. Although this reaction may occur spontaneously, the presence of isoforms M and A of the enzyme glutathione-S-transferase (GST) may increase its speed. Indeed, in pediatric patients with IBD, deletion of GST-M1, which determines reduced enzymatic activity, was recently associated with reduced sensitivity to azathioprine and reduced production of azathioprine active metabolites. In addition to increase the activation of azathioprine to mercaptopurine, GSTs may contribute to azathioprine effects even by modulating GSH consumption, oxidative stress and apoptosis. Therefore, genetic polymorphisms in genes for GSTs may be useful to predict response to azathioprine even if more in vitro and clinical validation studies are needed.

KW - Azathioprine

KW - Glutathione-S-transferase

KW - Inflammatory bowel disease

KW - Pediatric patients

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=84897526083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897526083&partnerID=8YFLogxK

U2 - 10.3748/wjg.v20.i13.3534

DO - 10.3748/wjg.v20.i13.3534

M3 - Article

C2 - 24707136

AN - SCOPUS:84897526083

VL - 20

SP - 3534

EP - 3541

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 13

ER -